Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1959 Sep;38(9):1487–1497. doi: 10.1172/JCI103927

PERSISTENCE OF ANTIBIOTICS IN BLOOD OF PATIENTS WITH ACUTE RENAL FAILURE. I. TETRACYCLINE AND CHLORTETRACYCLINE*,†

Calvin M Kunin 1,2,‡, Searle B Rees 1,2,§, John P Merrill 1,2,ǁ, Maxwell Finland 1,2
PMCID: PMC293280  PMID: 14412754

Full text

PDF
1489

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDRIOLA J. C. Further observations on the absorption, diffusion and excretion of tetracycline hydrochloride. Harlem Hosp Bull. 1954 Sep;7(2):69–72. [PubMed] [Google Scholar]
  2. BATEMAN J. C., BARBERIO J. R., GRICE P., KLOPP C. T., PIERPONT H. Fatal complications of intensive antibiotic therapy in patients with neoplastic disease. AMA Arch Intern Med. 1952 Dec;90(6):763–773. doi: 10.1001/archinte.1952.00240120038004. [DOI] [PubMed] [Google Scholar]
  3. Brod J., Sirota J. H. THE RENAL CLEARANCE OF ENDOGENOUS "CREATININE" IN MAN. J Clin Invest. 1948 Sep;27(5):645–654. doi: 10.1172/JCI102012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. COLE L. R. Recovery of aureomycin from the gastrointestinal tract following intravenous administration. J Lab Clin Med. 1953 May;41(5):670–675. [PubMed] [Google Scholar]
  5. FALOON W. W., DOWNS J. J., DUGGAN K., PRIOR J. T. Nitrogen and electrolyte metabolism and hepatic function and histology in patients receiving tetracyline. Am J Med Sci. 1957 May;233(5):563–572. doi: 10.1097/00000441-195705000-00011. [DOI] [PubMed] [Google Scholar]
  6. FALOON W. W. Metabolic and histologic studies in patients with and without liver disease receiving chloramphenicol and oxytetracycline. J Lab Clin Med. 1954 Jul;44(1):75–90. [PubMed] [Google Scholar]
  7. FALOON W. W., NOLL J. W., PRIOR J. T. Nitrogen metabolism and liver histology during aureomycin administration in patients with hepatic disease. J Lab Clin Med. 1953 Apr;41(4):596–607. [PubMed] [Google Scholar]
  8. FARHAT S. M., SCHELHART D. L., MUSSELMAN M. M. Clinical toxicity of antibiotics correlated with animal studies. AMA Arch Surg. 1958 May;76(5):762–765. doi: 10.1001/archsurg.1958.01280230102015. [DOI] [PubMed] [Google Scholar]
  9. GABUZDA G. J., GOCKE T. M., JACKSON G. G., GRIGSBY M. E., DEL LOVE B., Jr, FINLAND M. Some effects of antibiotics on nutrition in man; including studies of the bacterial flora of the feces. AMA Arch Intern Med. 1958 Feb;101(2):476–513. doi: 10.1001/archinte.1958.00260140308042. [DOI] [PubMed] [Google Scholar]
  10. GOCKE T. M., WELLS E. B., COLLINS H. S., FINLAND M. Blood levels and urinary excretion of aureomycin after intravenous and intramuscular administration. J Lab Clin Med. 1950 Jul;36(1):100–112. [PubMed] [Google Scholar]
  11. KUNIN C. M., FINLAND M. Demethylchlortetracycline; a new tetracycline antibiotic that yields greater and more sustained antibacterial activity. N Engl J Med. 1958 Nov 20;259(21):999–1005. doi: 10.1056/NEJM195811202592102. [DOI] [PubMed] [Google Scholar]
  12. KUNIN C. M., FINLAND M. Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin. J Clin Invest. 1959 Sep;38:1509–1519. doi: 10.1172/JCI103929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. KUNIN C. M., GLAZKO A. J., FINLAND M. Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J Clin Invest. 1959 Sep;38:1498–1508. doi: 10.1172/JCI103928. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. LEEVY C. M., ZINKE M. R., CHEY W. Y. Observations on the distribution of C14 oxytetracycline in man. Antibiot Annu. 1958;6:258–261. [PubMed] [Google Scholar]
  15. LEPPER M. H., WOLFE C. K., ZIMMERMAN H. J., CALDWELL E. R., Jr, SPIES H. W., DOWLING H. F. Effect of large doses of aureomycin on human liver. AMA Arch Intern Med. 1951 Sep;88(3):271–283. doi: 10.1001/archinte.1951.03810090002001. [DOI] [PubMed] [Google Scholar]
  16. MERRILL J. P., THORN G. W., WALTER C. W., CALLAHAN E. J., HOLLINGSWORTH SMITH L., Jr The use of an artificial kidney. I. Technique. J Clin Invest. 1950 Apr;29(4):412–424. doi: 10.1172/JCI102274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. MEYER R., STRAFFON R. A., REES S. B., GUILD W. R., MERRILL J. P. A laboratory and clinical evaluation of the Kolff coil kidney. J Lab Clin Med. 1958 May;51(5):715–723. [PubMed] [Google Scholar]
  18. Miller B. F., Winkler A. W. THE RENAL EXCRETION OF ENDOGENOUS CREATININE IN MAN. COMPARISON WITH EXOGENOUS CREATININE AND INULIN. J Clin Invest. 1938 Jan;17(1):31–40. doi: 10.1172/JCI100925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. doi: 10.1172/JCI103680. [DOI] [PMC free article] [Google Scholar]
  20. Paine T. F., Jr, Collins H. S., Finland M. Bacteriologic Studies on Aureomycin. J Bacteriol. 1948 Oct;56(4):489–497. doi: 10.1128/jb.56.4.489-497.1948. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. SBOROV V. M., SUTHERLAND D. A. Fatty liver following aureomycin and terramycin therapy in chronic hepatic disease. Gastroenterology. 1951 Aug;18(4):598–605. [PubMed] [Google Scholar]
  22. SIROTA J. H., SALTZMAN A., WARMBRAND H. The renal clearance and plasma protein binding of aureomycin in man. J Pharmacol Exp Ther. 1950 Oct;100(2):210–218. [PubMed] [Google Scholar]
  23. Steinitz K., Türkand H. THE DETERMINATION OF THE GLOMERULAR FILTRATION BY THE ENDOGENOUS CREATININE CLEARANCE. J Clin Invest. 1940 Mar;19(2):285–298. doi: 10.1172/JCI101131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. WEIL M. H., SPINK W. W. The schock syndrome associated with bacteremia due to gram-negative bacilli. AMA Arch Intern Med. 1958 Feb;101(2):184–193. doi: 10.1001/archinte.1958.00260140016004. [DOI] [PubMed] [Google Scholar]
  25. WOMACK C. R., JACKSON G. G., GOCKE T. M., KASS E. H., HAIGHT T. H., FINLAND M. Terramycin therapy of urinary tract infections. AMA Arch Intern Med. 1952 Feb;89(2):240–257. doi: 10.1001/archinte.1952.00240020072005. [DOI] [PubMed] [Google Scholar]
  26. WOMACK C. R., KASS E. H. A substance in egg yolk which inhibits deterioration of aureomycin activity. Proc Soc Exp Biol Med. 1949 Dec;72(3):706–708. doi: 10.3181/00379727-72-17550. [DOI] [PubMed] [Google Scholar]
  27. WOMACK C. R., KASS E. H., FINLAND M. Further observations on a substance in egg yolk which protects aureomycin from deterioration. J Lab Clin Med. 1950 Oct;36(4):655–659. [PubMed] [Google Scholar]
  28. WOOD W. S., KIPNIS G. P., SPIES H. W., DOWLING H. F., LEPPER M. H., JACKSON G. G. Tetracycline therapy: clinical and laboratory observations on one hundred eighty-four patients treated with tetracycline. AMA Arch Intern Med. 1954 Sep;94(3):351–363. doi: 10.1001/archinte.1954.00250030021004. [DOI] [PubMed] [Google Scholar]
  29. YESNER R., KUNKEL P. Preliminary observations on the effect of aureomycin, terramycin, tibione, combined tibione and streptomycin, and chloromycetin on the morphology of the liver in man. Yale J Biol Med. 1951 Feb;23(4):299–304. [PMC free article] [PubMed] [Google Scholar]
  30. ZASLOW J., HEWLETT T. H., GOLDSMITH R. The excretion and concentration of aureomycin in the abnormal human biliary tract. Gastroenterology. 1950 Oct;16(2):479–483. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES